An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

An international research team led by the Medical University of Vienna has demonstrated for the first time that thyroid hormone plays a key role in the development and progression of prostate cancer.

FX-909 has achieved clinical proof of concept in the Phase 1A trial as a monotherapy, and we are very pleased to announce this agreement with Merck to add a combination arm to our ongoing Phase 1 ...

Scientists have identified two enzymes that help prostate cancer cells grow, survive and resist treatment, paving the way for new treatments.

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...

Researchers at the University of Michigan have discovered a powerful new way to stop prostate cancer from growing—by ...

About one-third of all drugs approved by the Food and Drug Administration target the largest family of cell membrane ...

Two enzymes from the protein disulphide isomerase (PDI) family enable prostate cancer cells to grow, survive, and resist ...

ARPIs used in combination with ADT in prostate cancer significantly increased the risk for cardiovascular events.

(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...